<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM"><PMID Version="2">31098852</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>09</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1878-7479</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</Title><ISOAbbreviation>Neurotherapeutics</ISOAbbreviation></Journal><ArticleTitle>Targeted Oligonucleotides for Treating Neurodegenerative Tandem Repeat Diseases.</ArticleTitle><Pagination><StartPage>248</StartPage><EndPage>262</EndPage><MedlinePgn>248-262</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13311-019-00712-9</ELocationID><Abstract><AbstractText>Nucleotide repeat disorders encompass more than 30 diseases, most of which show dominant inheritance, such as Huntington's disease, spinocerebellar ataxias, and myotonic dystrophies. Yet others, including Friedreich's ataxia, are recessively inherited. A common feature is the presence of a DNA tandem repeat in the disease-associated gene and the propensity of the repeats to expand in germ and in somatic cells, with ensuing neurological and frequently also neuromuscular defects. Repeat expansion is the most frequent event in these diseases; however, sequence contractions, deletions, and mutations have also been reported. Nucleotide repeat sequences are predisposed to adopt non-B-DNA conformations, such as hairpins, cruciform, and intramolecular triple-helix structures (triplexes), also known as H-DNA. For gain-of-function disorders, oligonucleotides can be used to target either transcripts or duplex DNA and in diseases with recessive inheritance oligonucleotides may be used to alter repressive DNA or RNA conformations. Most current treatment strategies are aimed at altering transcript levels, but therapies directed against DNA are also emerging, and novel strategies targeting DNA, instead of RNA, are described. Different mechanisms using modified oligonucleotides are discussed along with the structural aspects of repeat sequences, which can influence binding modes and efficiencies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zain</LastName><ForeName>Rula</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-8327-846X</Identifier><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Centre for Advanced Therapies, Karolinska Institutet, Karolinska University Hospital, SE-141 86, Stockholm, Sweden. rula.zain@ki.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Genetics, Centre for Rare Diseases, Karolinska University Hospital, SE-171 76, Stockholm, Sweden. rula.zain@ki.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>C I Edvard</ForeName><Initials>CIE</Initials><Identifier Source="ORCID">0000-0003-1907-3392</Identifier><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Centre for Advanced Therapies, Karolinska Institutet, Karolinska University Hospital, SE-141 86, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2018-00177</GrantID><Agency>VINNOVA (SE)</Agency><Country>International</Country></Grant><Grant><GrantID>20180860</GrantID><Agency>Stockholms L?ns Landsting</Agency><Country>International</Country></Grant><Grant><GrantID>20180860</GrantID><Agency>Stockholms L?ns Landsting</Agency><Country>International</Country></Grant><Grant><GrantID>LS2016-1448</GrantID><Agency>Stockholms L?ns Landsting</Agency><Country>International</Country></Grant><Grant><GrantID>2017-02131</GrantID><Agency>Vetenskapsr?det</Agency><Country>International</Country></Grant><Grant><GrantID>CAN 17 0472</GrantID><Agency>Cancerfonden</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurotherapeutics</MedlineTA><NlmUniqueID>101290381</NlmUniqueID><ISSNLinking>1878-7479</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009841">Oligonucleotides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="N">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004260" MajorTopicYN="Y">DNA Repair</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005600" MajorTopicYN="N">Fragile X Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009690" MajorTopicYN="N">Nucleic Acid Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009841" MajorTopicYN="N">Oligonucleotides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020080" MajorTopicYN="Y">Tandem Repeat Sequences</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chromatin</Keyword><Keyword MajorTopicYN="N">DNA repair</Keyword><Keyword MajorTopicYN="N">fragile X syndrome</Keyword><Keyword MajorTopicYN="N">locked nucleic acid</Keyword><Keyword MajorTopicYN="N">non-canonical DNA structure</Keyword><Keyword MajorTopicYN="N">spinal and bulbar muscular atrophy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31098852</ArticleId><ArticleId IdType="pmc">PMC6554256</ArticleId><ArticleId IdType="doi">10.1007/s13311-019-00712-9</ArticleId><ArticleId IdType="pii">10.1007/s13311-019-00712-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Caskey CT, Pizzuti A, Fu YH, Fenwick RG, Jr, Nelson DL. Triplet repeat mutations in human disease. Science. 1992;256(5058):784&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">1589758</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirkin SM. Expandable DNA repeats and human disease. Nature. 2007;447(7147):932&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">17581576</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer RR, Pluciennik A, Napierala M, Wells RD. DNA triplet repeat expansion and mismatch repair. Annu Rev Biochem. 2015;84:199&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4845744</ArticleId><ArticleId IdType="pubmed">25580529</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannan AJ. Tandem repeats mediating genetic plasticity in health and disease. Nat Rev Genet. 2018;19(5):286&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">29398703</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinty RJ, Mirkin SM. Cis- and Trans-Modifiers of Repeat Expansions: Blending Model Systems with Human Genetics. Trends Genet. 2018;34(6):448&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5959756</ArticleId><ArticleId IdType="pubmed">29567336</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CIE, Zain R. Therapeutic Oligonucleotides: State of the Art. Annu Rev Pharmacol Toxicol. 2019;59:605&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">30285540</ArticleId></ArticleIdList></Reference><Reference><Citation>Caron NS, Dorsey ER, Hayden MR. Therapeutic approaches to Huntington disease: from the bench to the clinic. Nat Rev Drug Discov. 2018;17(10):729&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">30237454</ArticleId></ArticleIdList></Reference><Reference><Citation>Wurster CD, Ludolph AC. Antisense oligonucleotides in neurological disorders. Ther Adv Neurol Disord. 2018;11:1756286418776932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5971383</ArticleId><ArticleId IdType="pubmed">29854003</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulson HL, Shakkottai VG, Clark HB, Orr HT. Polyglutamine spinocerebellar ataxias - from genes to potential treatments. Nat Rev Neurosci. 2017;18(10):613&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6420820</ArticleId><ArticleId IdType="pubmed">28855740</ArticleId></ArticleIdList></Reference><Reference><Citation>Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M, Cavalcanti F, et al. Friedreich&#x2019;s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271(5254):1423&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8596916</ArticleId></ArticleIdList></Reference><Reference><Citation>Strawser C, Schadt K, Hauser L, McCormick A, Wells M, Larkindale J, et al. Pharmacological therapeutics in Friedreich ataxia: the present state. Expert Rev Neurother. 2017;17(9):895&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pubmed">28724340</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991;65(5):905&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">1710175</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry-Kravis EM, Lindemann L, Jonch AE, Apostol G, Bear MF, Carpenter RL, et al. Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. Nat Rev Drug Discov. 2018;17(4):280&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6904225</ArticleId><ArticleId IdType="pubmed">29217836</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberle I, Rousseau F, Heitz D, Kretz C, Devys D, Hanauer A, et al. Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science. 1991;252(5009):1097&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">2031184</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieretti M, Zhang FP, Fu YH, Warren ST, Oostra BA, Caskey CT, et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell. 1991;66(4):817&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">1878973</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall DA, Berry-Kravis E. Fragile X syndrome and fragile X-associated tremor ataxia syndrome. Handb Clin Neurol. 2018;147:377&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">29325626</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao XN, Usdin K. Timing of Expansion of Fragile X Premutation Alleles During Intergenerational Transmission in a Mouse Model of the Fragile X-Related Disorders. Front Genet. 2018;9:314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6096447</ArticleId><ArticleId IdType="pubmed">30147707</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Revenga L, Madrigal I, Pagonabarraga J, Xuncla M, Badenas C, Kulisevsky J, et al. Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families. Eur J Hum Genet. 2009;17(10):1359&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2986640</ArticleId><ArticleId IdType="pubmed">19367323</ArticleId></ArticleIdList></Reference><Reference><Citation>Eder PS, DeVine RJ, Dagle JM, Walder JA. Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3&#x2032; exonuclease in plasma. Antisense Res Dev. 1991;1(2):141&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">1841656</ArticleId></ArticleIdList></Reference><Reference><Citation>Sands H, Gorey-Feret LJ, Cocuzza AJ, Hobbs FW, Chidester D, Trainor GL. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol. 1994;45(5):932&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">8190109</ArticleId></ArticleIdList></Reference><Reference><Citation>Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol. 2017;35(3):238&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5517098</ArticleId><ArticleId IdType="pubmed">28244990</ArticleId></ArticleIdList></Reference><Reference><Citation>Herdewijn P. Heterocyclic modifications of oligonucleotides and antisense technology. Antisense Nucleic Acid Drug Dev. 2000;10(4):297&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">10984123</ArticleId></ArticleIdList></Reference><Reference><Citation>Deleavey GF, Damha MJ. Designing chemically modified oligonucleotides for targeted gene silencing. Chem Biol. 2012;19(8):937&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">22921062</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariko K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23(2):165&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">16111635</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibahara S, Mukai S, Nishihara T, Inoue H, Ohtsuka E, Morisawa H. Site-directed cleavage of RNA. Nucleic Acids Res. 1987;15(11):4403&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC340870</ArticleId><ArticleId IdType="pubmed">2438655</ArticleId></ArticleIdList></Reference><Reference><Citation>Monia BP, Lesnik EA, Gonzalez C, Lima WF, McGee D, Guinosso CJ, et al. Evaluation of 2&#x2032;-modified oligonucleotides containing 2&#x2032;-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem. 1993;268(19):14514&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">8390996</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar R, Singh SK, Koshkin AA, Rajwanshi VK, Meldgaard M, Wengel J. The first analogues of LNA (locked nucleic acids): phosphorothioate-LNA and 2&#x2032;-thio-LNA. Bioorg Med Chem Lett. 1998;8(16):2219&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">9873516</ArticleId></ArticleIdList></Reference><Reference><Citation>Koshkin A, Singh S, Nielsen P, et al. Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedon. 1998;54:3607&#x2013;30.</Citation></Reference><Reference><Citation>Obika S, Nanbu D, Hari Y, et al. Novel bicyclic nucleosides having a fixed C3&#x2019;-endo sugar puckering. Tetrahedon Letter. 1997;54:8735&#x2013;8.</Citation></Reference><Reference><Citation>Seth PP, Siwkowski A, Allerson CR, Vasquez G, Lee S, Prakash TP, et al. Short antisense oligonucleotides with novel 2&#x2032;-4&#x2032; conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J Med Chem. 2009;52(1):10&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">19086780</ArticleId></ArticleIdList></Reference><Reference><Citation>Pabon-Martinez YV, Xu Y, Villa A, Lundin KE, Geny S, Nguyen CH, et al. LNA effects on DNA binding and conformation: from single strand to duplex and triplex structures. Sci Rep. 2017;7(1):11043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5591256</ArticleId><ArticleId IdType="pubmed">28887512</ArticleId></ArticleIdList></Reference><Reference><Citation>Seth PP, Vasquez G, Allerson CA, Berdeja A, Gaus H, Kinberger GA, et al. Synthesis and biophysical evaluation of 2&#x2032;,4&#x2032;-constrained 2'O-methoxyethyl and 2&#x2032;,4&#x2032;-constrained 2'O-ethyl nucleic acid analogues. J Organomet Chem. 2010;75(5):1569&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">20136157</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckstein F. Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev. 2000;10(2):117&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10805163</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal S, Temsamani J, Tang JY. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A. 1991;88(17):7595&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC52348</ArticleId><ArticleId IdType="pubmed">1881900</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry SP, Seguin R, Cavagnaro J, Berman C, Tepper J, Kornbrust D. Considerations for the Characterization and Interpretation of Results Related to Alternative Complement Activation in Monkeys Associated with Oligonucleotide-Based Therapeutics. Nucleic Acid Ther. 2016;26(4):210&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">26981618</ArticleId></ArticleIdList></Reference><Reference><Citation>Crooke ST, Baker BF, Witztum JL, Kwoh TJ, Pham NC, Salgado N, et al. The Effects of 2'-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials. Nucleic Acid Ther. 2017;27(3):121&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5467133</ArticleId><ArticleId IdType="pubmed">28145801</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanan P, Shen L, Curtis BR, Bourdon MA, Nolan JP, Gupta S, et al. Investigation into the Mechanism(s) That Leads to Platelet Decreases in Cynomolgus Monkeys During Administration of ISIS 104838, a 2'-MOE-Modified Antisense Oligonucleotide. Toxicol Sci. 2018;164(2):613&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">29846725</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang XH, Sun H, Shen W, Crooke ST. Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages. Nucleic Acids Res. 2015;43(5):2927&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4357732</ArticleId><ArticleId IdType="pubmed">25712094</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidenreich O, Gryaznov S, Nerenberg M. RNase H-independent antisense activity of oligonucleotide N3 '--&gt; P5 ' phosphoramidates. Nucleic Acids Res. 1997;25(4):776&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC146512</ArticleId><ArticleId IdType="pubmed">9016628</ArticleId></ArticleIdList></Reference><Reference><Citation>Egholm M, Christensen L, Dueholm KL, Buchardt O, Coull J, Nielsen PE. Efficient pH-independent sequence-specific DNA binding by pseudoisocytosine-containing bis-PNA. Nucleic Acids Res. 1995;23(2):217&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC306657</ArticleId><ArticleId IdType="pubmed">7862524</ArticleId></ArticleIdList></Reference><Reference><Citation>Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 1997;7(3):187&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">9212909</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergquist H, Rocha CS, Alvarez-Asencio R, Nguyen CH, Rutland MW, Smith CI, et al. Disruption of Higher Order DNA Structures in Friedreich&#x2019;s Ataxia (GAA)n Repeats by PNA or LNA Targeting. PLoS One. 2016;11(11):e0165788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5112992</ArticleId><ArticleId IdType="pubmed">27846236</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen PE. Sequence-selective targeting of duplex DNA by peptide nucleic acids. Curr Opin Mol Ther. 2010;12(2):184&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">20373262</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno PM, Geny S, Pabon YV, Bergquist H, Zaghloul EM, Rocha CS, et al. Development of bis-locked nucleic acid (bisLNA) oligonucleotides for efficient invasion of supercoiled duplex DNA. Nucleic Acids Res. 2013;41(5):3257&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3597675</ArticleId><ArticleId IdType="pubmed">23345620</ArticleId></ArticleIdList></Reference><Reference><Citation>Geny S, Moreno PM, Krzywkowski T, Gissberg O, Andersen NK, Isse AJ, et al. Next-generation bis-locked nucleic acids with stacking linker and 2&#x2032;-glycylamino-LNA show enhanced DNA invasion into supercoiled duplexes. Nucleic Acids Res. 2016;44(5):2007&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4797291</ArticleId><ArticleId IdType="pubmed">26857548</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A. 1978;75(1):280&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC411230</ArticleId><ArticleId IdType="pubmed">75545</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci U S A. 1978;75(1):285&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC411231</ArticleId><ArticleId IdType="pubmed">75546</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundin KE, Gissberg O, Smith CI. Oligonucleotide Therapies: The Past and the Present. Hum Gene Ther. 2015;26(8):475&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4554547</ArticleId><ArticleId IdType="pubmed">26160334</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Matsui M, Gagnon KT, Schwartz JC, Gabillet S, Arar K, et al. Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol. 2009;27(5):478&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2765218</ArticleId><ArticleId IdType="pubmed">19412185</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyao MP, Auerbach AB, Ryan A, Persichetti F, Barnes GT, McNeil SM, et al. Inactivation of the mouse Huntington&#x2019;s disease gene homolog Hdh. Science. 1995;269(5222):407&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">7618107</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasir J, Floresco SB, O&#x2019;Kusky JR, Diewert VM, Richman JM, Zeisler J, et al. Targeted disruption of the Huntington&#x2019;s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell. 1995;81(5):811&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">7774020</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington&#x2019;s disease gene homologue. Nat Genet. 1995;11(2):155&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">7550343</ArticleId></ArticleIdList></Reference><Reference><Citation>White JK, Auerbach W, Duyao MP, Vonsattel JP, Gusella JF, Joyner AL, et al. Huntingtin is required for neurogenesis and is not impaired by the Huntington&#x2019;s disease CAG expansion. Nat Genet. 1997;17(4):404&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">9398841</ArticleId></ArticleIdList></Reference><Reference><Citation>McBride JL, Pitzer MR, Boudreau RL, Dufour B, Hobbs T, Ojeda SR, et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington&#x2019;s disease. Mol Ther. 2011;19(12):2152&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3242667</ArticleId><ArticleId IdType="pubmed">22031240</ArticleId></ArticleIdList></Reference><Reference><Citation>Grondin R, Kaytor MD, Ai Y, Nelson PT, Thakker DR, Heisel J, et al. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain. 2012;135(Pt 4):1197&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3326247</ArticleId><ArticleId IdType="pubmed">22252996</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragatsis I, Efstratiadis A, Zeitlin S. Mouse mutant embryos lacking huntingtin are rescued from lethality by wild-type extraembryonic tissues. Development. 1998;125(8):1529&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9502734</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietrich P, Johnson IM, Alli S, Dragatsis I. Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis. PLoS Genet. 2017;13(7):e1006846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5536499</ArticleId><ArticleId IdType="pubmed">28715425</ArticleId></ArticleIdList></Reference><Reference><Citation>Keiser MS, Kordower JH, Gonzalez-Alegre P, Davidson BL. Broad distribution of ataxin 1 silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy. Brain. 2015;138(Pt 12):3555&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4840549</ArticleId><ArticleId IdType="pubmed">26490326</ArticleId></ArticleIdList></Reference><Reference><Citation>Haque N, Isacson O. Antisense gene therapy for neurodegenerative disease? Exp Neurol. 1997;144(1):139&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">9126163</ArticleId></ArticleIdList></Reference><Reference><Citation>Yen L, Strittmatter SM, Kalb RG. Sequence-specific cleavage of Huntingtin mRNA by catalytic DNA. Ann Neurol. 1999;46(3):366&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">10482267</ArticleId></ArticleIdList></Reference><Reference><Citation>Nellemann C, Abell K, Norremolle A, Lokkegaard T, Naver B, Ropke C, et al. Inhibition of Huntington synthesis by antisense oligodeoxynucleotides. Mol Cell Neurosci. 2000;16(4):313&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">11085870</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, et al. Sustained therapeutic reversal of Huntington&#x2019;s disease by transient repression of huntingtin synthesis. Neuron. 2012;74(6):1031&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3383626</ArticleId><ArticleId IdType="pubmed">22726834</ArticleId></ArticleIdList></Reference><Reference><Citation>Evers MM, Pepers BA, van Deutekom JC, Mulders SA, den Dunnen JT, Aartsma-Rus A, et al. Targeting several CAG expansion diseases by a single antisense oligonucleotide. PLoS One. 2011;6(9):e24308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3164722</ArticleId><ArticleId IdType="pubmed">21909428</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y, Zu T, Low WC, Orr HT, McIvor RS. Antisense RNA sequences modulating the ataxin-1 message: molecular model of gene therapy for spinocerebellar ataxia type 1, a dominant-acting unstable trinucleotide repeat disease. Cell Transplant. 2008;17(7):723&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">19044200</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulders SA, van den Broek WJ, Wheeler TM, Croes HJ, van Kuik-Romeijn P, de Kimpe SJ, et al. Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S A. 2009;106(33):13915&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2728995</ArticleId><ArticleId IdType="pubmed">19667189</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahashi K, Katsuno M, Hung G, Adachi H, Kondo N, Nakatsuji H, et al. Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet. 2015;24(21):5985&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">26231218</ArticleId></ArticleIdList></Reference><Reference><Citation>Toonen LJA, Rigo F, van Attikum H, van Roon-Mom WMC. Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice. Mol Ther Nucleic Acids. 2017;8:232&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5504086</ArticleId><ArticleId IdType="pubmed">28918024</ArticleId></ArticleIdList></Reference><Reference><Citation>Warby SC, Montpetit A, Hayden AR, Carroll JB, Butland SL, Visscher H, et al. CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am J Hum Genet. 2009;84(3):351&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668007</ArticleId><ArticleId IdType="pubmed">19249009</ArticleId></ArticleIdList></Reference><Reference><Citation>Southwell AL, Skotte NH, Kordasiewicz HB, Ostergaard ME, Watt AT, Carroll JB, et al. In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Mol Ther. 2014;22(12):2093&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4429695</ArticleId><ArticleId IdType="pubmed">25101598</ArticleId></ArticleIdList></Reference><Reference><Citation>Southwell AL, Kordasiewicz HB, Langbehn D, Skotte NH, Parsons MP, Villanueva EB, et al. Huntingtin suppression restores cognitive function in a mouse model of Huntington&#x2019;s disease. Sci Transl Med 2018;10(461).</Citation><ArticleIdList><ArticleId IdType="pubmed">30282695</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostergaard ME, Southwell AL, Kordasiewicz H, Watt AT, Skotte NH, Doty CN, et al. Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res. 2013;41(21):9634&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834808</ArticleId><ArticleId IdType="pubmed">23963702</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll JB, Warby SC, Southwell AL, Doty CN, Greenlee S, Skotte N, et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. Mol Ther. 2011;19(12):2178&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3242664</ArticleId><ArticleId IdType="pubmed">21971427</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50:259&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">20055705</ArticleId></ArticleIdList></Reference><Reference><Citation>Didiot MC, Ferguson CM, Ly S, Coles AH, Smith AO, Bicknell AA, et al. Nuclear Localization of Huntingtin mRNA Is Specific to Cells of Neuronal Origin. Cell Rep. 2018;24(10):2553&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6245656</ArticleId><ArticleId IdType="pubmed">30184490</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT, et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med. 2004;10(8):816&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">15235598</ArticleId></ArticleIdList></Reference><Reference><Citation>Keiser MS, Geoghegan JC, Boudreau RL, Lennox KA, Davidson BL. RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1. Neurobiol Dis. 2013;56:6&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4173078</ArticleId><ArticleId IdType="pubmed">23583610</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves S, Nascimento-Ferreira I, Dufour N, Hassig R, Auregan G, Nobrega C, et al. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3? Hum Mol Genet. 2010;19(12):2380&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">20308049</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfister EL, Kennington L, Straubhaar J, Wagh S, Liu W, DiFiglia M, et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington&#x2019;s disease patients. Curr Biol. 2009;19(9):774&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2746439</ArticleId><ArticleId IdType="pubmed">19361997</ArticleId></ArticleIdList></Reference><Reference><Citation>Miniarikova J, Zimmer V, Martier R, Brouwers CC, Pythoud C, Richetin K, et al. AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington&#x2019;s disease. Gene Ther. 2017;24(10):630&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5658675</ArticleId><ArticleId IdType="pubmed">28771234</ArticleId></ArticleIdList></Reference><Reference><Citation>Evers MM, Miniarikova J, Juhas S, Valles A, Bohuslavova B, Juhasova J, et al. AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington&#x2019;s Disease Minipig Model. Mol Ther. 2018;26(9):2163&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6127509</ArticleId><ArticleId IdType="pubmed">30007561</ArticleId></ArticleIdList></Reference><Reference><Citation>Rui Y, Wilson DR, Green JJ. Non-Viral Delivery To Enable Genome Editing. Trends Biotechnol 2019; 37(3):281&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6378131</ArticleId><ArticleId IdType="pubmed">30278987</ArticleId></ArticleIdList></Reference><Reference><Citation>Knott GJ, Doudna JA. CRISPR-Cas guides the future of genetic engineering. Science. 2018;361(6405):866&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6455913</ArticleId><ArticleId IdType="pubmed">30166482</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin JW, Kim KH, Chao MJ, Atwal RS, Gillis T, MacDonald ME, et al. Permanent inactivation of Huntington&#x2019;s disease mutation by personalized allele-specific CRISPR/Cas9. Hum Mol Genet. 2016;25(20):4566&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6078600</ArticleId><ArticleId IdType="pubmed">28172889</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, Chang R, Yang H, Zhao T, Hong Y, Kong HE, et al. CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington&#x2019;s disease. J Clin Invest. 2017;127(7):2719&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5490741</ArticleId><ArticleId IdType="pubmed">28628038</ArticleId></ArticleIdList></Reference><Reference><Citation>Dabrowska M, Juzwa W, Krzyzosiak WJ, Olejniczak M. Precise Excision of the CAG Tract from the Huntingtin Gene by Cas9 Nickases. Front Neurosci. 2018;12:75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5834764</ArticleId><ArticleId IdType="pubmed">29535594</ArticleId></ArticleIdList></Reference><Reference><Citation>Park CY, Halevy T, Lee DR, Sung JJ, Lee JS, Yanuka O, et al. Reversion of FMR1 Methylation and Silencing by Editing the Triplet Repeats in Fragile X iPSC-Derived Neurons. Cell Rep. 2015;13(2):234&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">26440889</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouellet DL, Cherif K, Rousseau J, Tremblay JP. Deletion of the GAA repeats from the human frataxin gene using the CRISPR-Cas9 system in YG8R-derived cells and mouse models of Friedreich ataxia. Gene Ther. 2017;24(5):265&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">28024081</ArticleId></ArticleIdList></Reference><Reference><Citation>Marthaler AG, Schmid B, Tubsuwan A, Poulsen UB, Engelbrecht AF, Mau-Holzmann UA, et al. Generation of an isogenic, gene-corrected control cell line of the spinocerebellar ataxia type 2 patient-derived iPSC line H196. Stem Cell Res. 2016;16(1):162&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">27345804</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouyang S, Xie Y, Xiong Z, Yang Y, Xian Y, Ou Z, et al. CRISPR/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells. Stem Cells Dev. 2018;27(11):756&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">29661116</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto BS, Saxena T, Oliveira R, Mendez-Gomez HR, Cleary JD, Denes LT, et al. Impeding Transcription of Expanded Microsatellite Repeats by Deactivated Cas9. Mol Cell. 2017;68(3):479&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6013302</ArticleId><ArticleId IdType="pubmed">29056323</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarrington RM, Verma S, Schwartz S, Trautman JK, Carroll D. Nucleosomes inhibit target cleavage by CRISPR-Cas9 in vivo. Proc Natl Acad Sci U S A. 2018;115(38):9351&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6156633</ArticleId><ArticleId IdType="pubmed">30201707</ArticleId></ArticleIdList></Reference><Reference><Citation>Batra R, Nelles DA, Pirie E, Blue SM, Marina RJ, Wang H, et al. Elimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9. Cell. 2017;170(5):899&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5873302</ArticleId><ArticleId IdType="pubmed">28803727</ArticleId></ArticleIdList></Reference><Reference><Citation>Groh M, Silva LM, Gromak N. Mechanisms of transcriptional dysregulation in repeat expansion disorders. Biochem Soc Trans. 2014;42(4):1123&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25110013</ArticleId></ArticleIdList></Reference><Reference><Citation>Punga T, Buhler M. Long intronic GAA repeats causing Friedreich ataxia impede transcription elongation. EMBO Mol Med. 2010;2(4):120&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3377279</ArticleId><ArticleId IdType="pubmed">20373285</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim E, Napierala M, Dent SY. Hyperexpansion of GAA repeats affects post-initiation steps of FXN transcription in Friedreich&#x2019;s ataxia. Nucleic Acids Res. 2011;39(19):8366&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3201871</ArticleId><ArticleId IdType="pubmed">21745819</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabhan JF, Wood KM, Rao VP, Morin J, Bhamidipaty S, LaBranche TP, et al. Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich&#x2019;s ataxia. Sci Rep. 2016;6:20019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4756688</ArticleId><ArticleId IdType="pubmed">26883577</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Matsui M, Corey DR. Activating frataxin expression by repeat-targeted nucleic acids. Nat Commun. 2016;7:10606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4742999</ArticleId><ArticleId IdType="pubmed">26842135</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Shen X, Liu Z, Norrbom M, Prakash TP, O&#x2019;Reilly D, et al. Activation of Frataxin Protein Expression by Antisense Oligonucleotides Targeting the Mutant Expanded Repeat. Nucleic Acid Ther. 2018;28(1):23&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5790436</ArticleId><ArticleId IdType="pubmed">29341839</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabczyk E, Mancuso M, Sammarco MC. A persistent RNA.DNA hybrid formed by transcription of the Friedreich ataxia triplet repeat in live bacteria, and by T7 RNAP in vitro. Nucleic Acids Res. 2007;35(16):5351&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2018641</ArticleId><ArticleId IdType="pubmed">17693431</ArticleId></ArticleIdList></Reference><Reference><Citation>Groh M, Lufino MM, Wade-Martins R, Gromak N. R-loops associated with triplet repeat expansions promote gene silencing in Friedreich ataxia and fragile X syndrome. PLoS Genet. 2014;10(5):e1004318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4006715</ArticleId><ArticleId IdType="pubmed">24787137</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran T, Childs-Disney JL, Liu B, Guan L, Rzuczek S, Disney MD. Targeting the r(CGG) repeats that cause FXTAS with modularly assembled small molecules and oligonucleotides. ACS Chem Biol. 2014;9(4):904&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4287843</ArticleId><ArticleId IdType="pubmed">24506227</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelechano V, Steinmetz LM. Gene regulation by antisense transcription. Nat Rev Genet. 2013;14(12):880&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">24217315</ArticleId></ArticleIdList></Reference><Reference><Citation>Katayama S, Tomaru Y, Kasukawa T, Waki K, Nakanishi M, Nakamura M, et al. Antisense transcription in the mammalian transcriptome. Science. 2005;309(5740):1564&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16141073</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozsolak F, Kapranov P, Foissac S, Kim SW, Fishilevich E, Monaghan AP, et al. Comprehensive polyadenylation site maps in yeast and human reveal pervasive alternative polyadenylation. Cell. 2010;143(6):1018&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3022516</ArticleId><ArticleId IdType="pubmed">21145465</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho DH, Thienes CP, Mahoney SE, Analau E, Filippova GN, Tapscott SJ. Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF. Mol Cell. 2005;20(3):483&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16285929</ArticleId></ArticleIdList></Reference><Reference><Citation>De Biase I, Chutake YK, Rindler PM, Bidichandani SI. Epigenetic silencing in Friedreich ataxia is associated with depletion of CTCF (CCCTC-binding factor) and antisense transcription. PLoS One. 2009;4(11):e7914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2780319</ArticleId><ArticleId IdType="pubmed">19956589</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung DW, Rudnicki DD, Yu L, Margolis RL. A natural antisense transcript at the Huntington&#x2019;s disease repeat locus regulates HTT expression. Hum Mol Genet. 2011;20(17):3467&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3153309</ArticleId><ArticleId IdType="pubmed">21672921</ArticleId></ArticleIdList></Reference><Reference><Citation>Li PP, Sun X, Xia G, Arbez N, Paul S, Zhu S, et al. ATXN2-AS, a gene antisense to ATXN2, is associated with spinocerebellar ataxia type 2 and amyotrophic lateral sclerosis. Ann Neurol. 2016;80(4):600&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6555153</ArticleId><ArticleId IdType="pubmed">27531668</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans-Galea MV, Lockhart PJ, Galea CA, Hannan AJ, Delatycki MB. Beyond loss of frataxin: the complex molecular pathology of Friedreich ataxia. Discov Med. 2014;17(91):25&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">24411698</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikaeili H, Sandi M, Bayot A, Al-Mahdawi S, Pook MA. FAST-1 antisense RNA epigenetically alters FXN expression. Sci Rep. 2018;8(1):17217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6249312</ArticleId><ArticleId IdType="pubmed">30464193</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaghloul EM, Gissberg O, Moreno PMD, Siggens L, Hallbrink M, Jorgensen AS, et al. CTG repeat-targeting oligonucleotides for down-regulating Huntingtin expression. Nucleic Acids Res. 2017;45(9):5153&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5435994</ArticleId><ArticleId IdType="pubmed">28334749</ArticleId></ArticleIdList></Reference><Reference><Citation>Gacy AM, Goellner G, Juranic N, Macura S, McMurray CT. Trinucleotide repeats that expand in human disease form hairpin structures in vitro. Cell. 1995;81(4):533&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">7758107</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan F, Man VH, Roland C, Sagui C. Structure and Dynamics of DNA and RNA Double Helices of CAG and GAC Trinucleotide Repeats. Biophys J. 2017;113(1):19&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5510815</ArticleId><ArticleId IdType="pubmed">28700917</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan F, Man VH, Roland C, Sagui C. Structure and Dynamics of DNA and RNA Double Helices Obtained from the CCG and GGC Trinucleotide Repeats. J Phys Chem B. 2018;122(16):4491&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6475210</ArticleId><ArticleId IdType="pubmed">29617130</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan F, Zhang Y, Man VH, Roland C, Sagui C. E-motif formed by extrahelical cytosine bases in DNA homoduplexes of trinucleotide and hexanucleotide repeats. Nucleic Acids Res. 2018;46(2):942&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5778509</ArticleId><ArticleId IdType="pubmed">29190385</ArticleId></ArticleIdList></Reference><Reference><Citation>Gacy AM, McMurray CT. Influence of hairpins on template reannealing at trinucleotide repeat duplexes: a model for slipped DNA. Biochemistry. 1998;37(26):9426&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">9649325</ArticleId></ArticleIdList></Reference><Reference><Citation>Colak D, Zaninovic N, Cohen MS, Rosenwaks Z, Yang WY, Gerhardt J, et al. Promoter-bound trinucleotide repeat mRNA drives epigenetic silencing in fragile X syndrome. Science. 2014;343(6174):1002&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4357282</ArticleId><ArticleId IdType="pubmed">24578575</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun JH, Zhou L, Emerson DJ, Phyo SA, Titus KR, Gong W, et al. Disease-Associated Short Tandem Repeats Co-localize with Chromatin Domain Boundaries. Cell. 2018;175(1):224&#x2013;38.e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6175607</ArticleId><ArticleId IdType="pubmed">30173918</ArticleId></ArticleIdList></Reference><Reference><Citation>Eimer H, Sureshkumar S, Singh Yadav A, Kraupner-Taylor C, Bandaranayake C, Seleznev A, et al. RNA-Dependent Epigenetic Silencing Directs Transcriptional Downregulation Caused by Intronic Repeat Expansions. Cell. 2018;174(5):1095&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">30057112</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurray CT. Mechanisms of trinucleotide repeat instability during human development. Nat Rev Genet. 2010;11(11):786&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175376</ArticleId><ArticleId IdType="pubmed">20953213</ArticleId></ArticleIdList></Reference><Reference><Citation>Long A, Napierala JS, Polak U, Hauser L, Koeppen AH, Lynch DR, et al. Somatic instability of the expanded GAA repeats in Friedreich&#x2019;s ataxia. PLoS One. 2017;12(12):e0189990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5736210</ArticleId><ArticleId IdType="pubmed">29261783</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirkin SM, Frank-Kamenetskii MD. H-DNA and related structures. Annu Rev Biophys Biomol Struct. 1994;23:541&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">7919793</ArticleId></ArticleIdList></Reference><Reference><Citation>Napierala M, Bacolla A, Wells RD. Increased negative superhelical density in vivo enhances the genetic instability of triplet repeat sequences. J Biol Chem. 2005;280(45):37366&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">16166072</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Shishkin AA, Nishida Y, Marcinkowski-Desmond D, Saini N, Volkov KV, et al. Genome-wide screen identifies pathways that govern GAA/TTC repeat fragility and expansions in dividing and nondividing yeast cells. Mol Cell. 2012;48(2):254&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3635072</ArticleId><ArticleId IdType="pubmed">22959270</ArticleId></ArticleIdList></Reference><Reference><Citation>Genetic Modifiers of Huntington&#x2019;s Disease C Identification of Genetic Factors that Modify Clinical Onset of Huntington&#x2019;s Disease. Cell. 2015;162(3):516&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4524551</ArticleId><ArticleId IdType="pubmed">26232222</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmans PA, Massey TH, Jones L. Genetic modifiers of Mendelian disease: Huntington&#x2019;s disease and the trinucleotide repeat disorders. Hum Mol Genet. 2017;26(R2):R83&#x2013;R90.</Citation><ArticleIdList><ArticleId IdType="pubmed">28977442</ArticleId></ArticleIdList></Reference><Reference><Citation>Razidlo DF, Lahue RS. Mrc1, Tof1 and Csm3 inhibit CAG.CTG repeat instability by at least two mechanisms. DNA Repair (Amst) 2008;7(4):633&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2396238</ArticleId><ArticleId IdType="pubmed">18321795</ArticleId></ArticleIdList></Reference><Reference><Citation>Dervan PB, Edelson BS. Recognition of the DNA minor groove by pyrrole-imidazole polyamides. Curr Opin Struct Biol. 2003;13(3):284&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">12831879</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett R, Melander C, Puckett JW, Son LS, Wells RD, Dervan PB, et al. DNA sequence-specific polyamides alleviate transcription inhibition associated with long GAA.TTC repeats in Friedreich&#x2019;s ataxia. Proc Natl Acad Sci U S A. 2006;103(31):11497&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1544198</ArticleId><ArticleId IdType="pubmed">16857735</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssen S, Cuvier O, Muller M, Laemmli UK. Specific gain- and loss-of-function phenotypes induced by satellite-specific DNA-binding drugs fed to Drosophila melanogaster. Mol Cell. 2000;6(5):1013&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">11106741</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerhardt J, Bhalla AD, Butler JS, Puckett JW, Dervan PB, Rosenwaks Z, et al. Stalled DNA Replication Forks at the Endogenous GAA Repeats Drive Repeat Expansion in Friedreich&#x2019;s Ataxia Cells. Cell Rep. 2016;16(5):1218&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5028224</ArticleId><ArticleId IdType="pubmed">27425605</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergquist H, Nikravesh A, Fernandez RD, Larsson V, Nguyen CH, Good L, et al. Structure-specific recognition of Friedreich&#x2019;s ataxia (GAA)n repeats by benzoquinoquinoxaline derivatives. Chembiochem. 2009;10(16):2629&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">19746387</ArticleId></ArticleIdList></Reference><Reference><Citation>Potaman VN, Oussatcheva EA, Lyubchenko YL, Shlyakhtenko LS, Bidichandani SI, Ashizawa T, et al. Length-dependent structure formation in Friedreich ataxia (GAA)n*(TTC)n repeats at neutral pH. Nucleic Acids Res. 2004;32(3):1224&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC373408</ArticleId><ArticleId IdType="pubmed">14978261</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>